OUR MISSION

To transform the lives of individuals living with spinal cord injury.

Abstract blue cross shape with flowing dark teal wave lines on a solid black background.
Abstract soft light blue gradient glow on a solid white background.

OUR VISION

A future where damage to the central nervous system is no longer permanent. Where recovery is not just hoped for, but expected. We are restoring life's possibilities.

ZERO

Approved pharmacologic treatments for spinal cord injury.

Despite decades of research, there are no FDA-approved pharmacologic therapies capable of restoring function after spinal cord injury. NervGen exists to change that.

Teal and blue gradient curved arrow pointing to the right on a white background.
A Personal
Mission,
A Scientific
Breakthrough
Teal and blue gradient curved arrow pointing to the left on a white background.

NervGen was founded at the intersection of personal experience and scientific discovery. After a spinal cord injury left the daughter-in-law of co-founder Dr. Harold Punnett paralyzed, he began searching for a solution, determined to find a path to recovery. That search led him to the pioneering work of neuroscientist Dr. Jerry Silver, whose research identified a key barrier to nervous system repair. In 2017, NervGen was established to translate the breakthrough science of Dr. Silver into therapies designed to enable the nervous system to repair itself.

Circular Graph
Dr. Jerry Silver in a white lab coat sitting in front of an office bookshelf with medical books and framed certificates.
Watch the
Origin Story
Abstract light blue curved lines forming a wave pattern on a solid white background.

CAREERS

At NervGen, we are united by a shared mission

We bring together scientists, clinicians, and industry professionals across disciplines who are driven by curiosity, collaboration, and a commitment to advancing breakthrough science.

NervGen Pharma executives celebrating and clapping at the Nasdaq opening bell ceremony with falling confetti.

Join us in shaping the future of neuroreparative therapeutics.

CONTACT US